RetinAI Medical

RetinAI develops Discovery, a software platform that collects, harmonises and analyses retinal imaging and other medical data, with CE-marked and research-use-only AI models for OCT layer and fluid segmentation and related biomarkers. The company states the platform is CE marked as a Class IIa medical device and that its platform and three AI models were certified under the EU Medical Devices Regulation in 2024.

Its customers are healthcare professionals, clinics and hospitals, pharmaceutical and life-science companies, and clinical and academic researchers. The website lists services for clinical trials, real-world evidence and multicenter collaborations. The website does not describe the revenue model in detail.

RetinAI was founded in 2017 and is run from Bern, Switzerland, where its parent Ikerian AG is headquartered; RetinAI US Inc. is located in Boston, Massachusetts. The website reports 125+ team members and open roles in Bern, Madrid and several US cities, including Head of Operations, Head of Quality and Regulatory Affairs, and Clinical Site Support Specialist.

Product: Discovery, a data management and AI analysis platform for ophthalmology imaging, with CE-marked and research-use-only AI models.